Related references
Note: Only part of the references are listed.Virologic Failure Following Low-level Viremia and Viral Blips During Antiretroviral Therapy: Results From a European Multicenter Cohort
Olof Elvstam et al.
CLINICAL INFECTIOUS DISEASES (2023)
Low-level viral loads and virological failure in the integrase strand transfer era
Lise Cuzin et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2023)
Impact of pre-antiretroviral treatment HIV-RNA on time to successful virological suppression and subsequent virological failure - two nationwide, population-based cohort studies
Erik Sorstedt et al.
AIDS (2023)
Clonally expanded HIV-1 proviruses with 5?-leader defects can give rise to nonsuppressible residual viremia
Jennifer A. White et al.
JOURNAL OF CLINICAL INVESTIGATION (2023)
Lower Incidence of HIV-1 Blips Observed During Integrase Inhibitor-Based Combination Antiretroviral Therapy
Suzan Dijkstra et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2022)
Predictors of low-level HIV viraemia and virological failure in the era of integrase inhibitors: A Spanish nationwide cohort
Hortensia Alvarez et al.
HIV MEDICINE (2022)
Predictors of Virological Failure and Time to Viral Suppression of First-Line Integrase Inhibitor-Based Antiretroviral Treatment
Ashima Pyngottu et al.
CLINICAL INFECTIOUS DISEASES (2021)
Durability of rilpivirine-based versus integrase inhibitor-based regimens in a large cohort of naive HIV-infected patients starting antiretroviral therapy
Roberta Gagliardini et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2021)
HIV-1 viral blips are associated with repeated and increasingly high levels of cell-associated HIV-1 RNA transcriptional activity
Kazuo Suzuki et al.
AIDS (2021)
Effectiveness of integrase strand transfer inhibitor-based regimens in HIV-infected treatment-naive individuals: results from a European multi-cohort study
Barbara Rossetti et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2021)
The multifaceted nature of HIV latency
Caroline Dufour et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
How to RESPOND to Modern Challenges for People Living with HIV: A Profile for a New Cohort Consortium
Bastian Neesgaard et al.
MICROORGANISMS (2020)
HIV-1 viremia not suppressible by antiretroviral therapy can originate from large T cell clones producing infectious virus
Elias K. Halvas et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Cells producing residual viremia during antiretroviral treatment appear to contribute to rebound viremia following interruption of treatment
Hadega A. Aamer et al.
PLOS PATHOGENS (2020)
Persistent Low-level Viremia While on Antiretroviral Therapy Is an Independent Risk Factor for Virologic Failure
Christie Joya et al.
CLINICAL INFECTIOUS DISEASES (2019)
INSTI-Based Triple Regimens in Treatment-Naive HIV-Infected Patients Are Associated With HIV-RNA Viral Load Suppression at Ultralow Levels
Sidonie Lambert-Niclot et al.
OPEN FORUM INFECTIOUS DISEASES (2019)
Low-level viremia and virologic failure in persons with HIV infection treated with antiretroviral therapy
Julia Fleming et al.
AIDS (2019)
Determinants of HIV-1 reservoir size and long-term dynamics during suppressive ART
Nadine Bachmann et al.
NATURE COMMUNICATIONS (2019)
Persistent Low-level Viremia Predicts Subsequent Virologic Failure: Is It Time to Change the Third 90?
Allahna Esber et al.
CLINICAL INFECTIOUS DISEASES (2019)
Low-Level Viremia Is Associated With Clinical Progression in HIV-Infected Patients Receiving Antiretroviral Treatment
Enrique Bernal et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2018)
Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided South African treatment programmes: a multicentre cohort study
Lucas E. Hermans et al.
LANCET INFECTIOUS DISEASES (2018)
Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 Results
Jose R. Arribas et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2017)
Longitudinal sequencing of HIV-1 infected patients with low-level viremia for years while on ART shows no indications for genetic evolution of the virus
Leen Vancoillie et al.
VIROLOGY (2017)
Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial
Pedro Cahn et al.
LANCET HIV (2017)
Viral blips were infrequent in treatment-naive adults treated with rilpivirine/emtricitabine/tenofovir DF or efavirenz emtricitabine/tenofovir DF through 96 weeks
Danielle P. Porter et al.
ANTIVIRAL THERAPY (2017)
Any impact of blips and low-level viraemia episodes among HIV-infected patients with sustained virological suppression on ART?
Berta Pernas et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
Viral blips during suppressive antiretroviral treatment are associated with high baseline HIV-1 RNA levels
Erik Sorstedt et al.
BMC INFECTIOUS DISEASES (2016)
Persistent HIV-1 replication maintains the tissue reservoir during therapy
Ramon Lorenzo-Redondo et al.
NATURE (2016)
Transient detectable viremia and the risk of viral rebound in patients from the Swiss HIV Cohort Study
Jim Young et al.
BMC INFECTIOUS DISEASES (2015)
Low-level HIV-1 viraemia in patients on HAART: risk factors and management in clinical practice
Marc Wirden et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2015)
Impact of low-level viremia on clinical and virological outcomes in treated HIV-1-infected patients
Marie-Anne Vandenhende et al.
AIDS (2015)
HIV drug resistance detected during low-level viraemia is associated with subsequent virologic failure
Luke C. Swenson et al.
AIDS (2014)
Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study
Bonaventura Clotet et al.
LANCET (2014)
Residual Viremia Is Preceding Viral Blips and Persistent Low-Level Viremia in Treated HIV-1 Patients
Laura Marije Hofstra et al.
PLOS ONE (2014)
Virologic Failure Following Persistent Low-level Viremia in a Cohort of HIV-Positive Patients: Results From 12 Years of Observation
Claudie Laprise et al.
CLINICAL INFECTIOUS DISEASES (2013)
Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial
Francois Raffi et al.
LANCET INFECTIOUS DISEASES (2013)
Dolutegravir plus Abacavir-Lamivudine for the Treatment of HIV-1 Infection
Sharon L. Walmsley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial
Joseph J. Eron et al.
LANCET INFECTIOUS DISEASES (2011)
Abacavir-Lamivudine versus Tenofovir-Emtricitabine for Initial HIV-1 Therapy
Paul E. Sax et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia
Frank Maldarelli et al.
PLOS PATHOGENS (2007)
Evidence that low-level viremias during effective highly active antiretroviral therapy result from two processes: Expression of archival virus and replication of virus
NH Tobin et al.
JOURNAL OF VIROLOGY (2005)
Factors affecting adherence to antiretroviral therapy
MA Chesney
CLINICAL INFECTIOUS DISEASES (2000)
Share Paper
